Search clinical trials for: Brolucizumab 6mg

Total 12092 results

Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD)

Macular Polypoidal Choroidal Vasculopathy (PCV)

Korea, Republic of
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals

Recruiting

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Neovascular Age-related Macular Degeneration

United Arab Emirates
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) (PEREGRINE)

Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals

Completed

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Neovascular Age-related Macular Degeneration

Japan
Novartis Pharmaceuticals

Not yet recruiting

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Diabetic Macular Edema
Novartis Pharmaceuticals

Terminated

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice (BESRA)

Neovascular Age-related Macular Degeneration

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (BLUE SKY)

Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)

Germany
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal (BLUESKY-PT)

Neovascular Age-related Macular Degeneration (nAMD)

Portugal
Novartis Pharmaceuticals

Completed

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Wet Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Benha University

Unknown

BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Dystrophy, Retinal

United Arab Emirates
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (CONDOR)

Proliferative Diabetic Retinopathy

China, India, Japan, Russian Federation, Turkey, Canada, United States, Australia, Korea, Republic of, Brazil, Philippines, Puerto Rico, Taiwan, Argentina, Chile, Mexico
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection

Diabetic Macular Edema

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Novartis Pharmaceuticals

Recruiting

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Neovascular Age-related Macular Degeneration

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Yeungnam University College of Medicine
Novartis

Not yet recruiting

Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy (PABLO)

Age-Related Macular Degeneration | Pachychoroid Neovasculopathy
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Helixmith Co., Ltd.

Completed

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

Critical Limb Ischemia

United States
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
Novartis Pharmaceuticals

Completed

Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Intraocular Inflammation | Retinal Vascular Occlusion

Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)

Neovascular Age-Related Macular Degeneration

France
Novartis Pharmaceuticals

Completed

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (OCTOPUS)

Neovascular Age Related Macular Degeneration

France
Novartis Pharmaceuticals

Completed

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (IMAGINE)

Neovascular Age-related Macular Degeneration

Italy
Universitaire Ziekenhuizen KU Leuven

Active, not recruiting

Beovu Experience UZ Leuven (BEL)

Age-Related Macular Degeneration

Belgium
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Vista Klinik
Novartis

Terminated

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (ROBIN)

Neovascular Age-related Macular Degeneration

Switzerland
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD)

India
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Macular Edema

United Arab Emirates
Pfizer

Completed

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Hepatitis C Virus

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
University of Edinburgh
NHS Lothian

Completed

Cardiovascular Effects of Apelin In Healthy Volunteers

Healthy

United Kingdom
Hangzhou Grand Biologic Pharmaceutical, Inc.
Peking Union Medical College Hospital

Unknown

Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

Healthy Participants

China
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
Hanmi Pharmaceutical Company Limited

Completed

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet (PGP inhibitor)

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Johns Hopkins University
Cultivate Biologics

Completed

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Cannabis

United States
Sunovion

Completed

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States
Mitsubishi Tanabe Pharma Corporation

Completed

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States, Puerto Rico
Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia
Yuhan Corporation

Completed

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Functional Constipation

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
GeneScience Pharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

China

3

Subscribe